Search the database for deliberate release of GM medicinal products
Displaying 1 - 4 of 4
|EU record number
|Company / Sponsor
|Only notified under the "contained use" procedure. Dossier submitted on 03/05/2021.
|Administration of genetically engineered T cells (KTE-X19) in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
|Only notified under the "contained use" procedure. Dossier submitted on 25/04/2018.
|A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
|Chimeric antigen receptor against CD19
|Only notified under the "contained use" procedure. Dossier submitted on 24/04/2017.
|A Phase 1, Open Label, Non-comparative Study to Evaluate the Safety and the Ability of UCART19 to Induce Molecular Remission in Paediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukaemia
|Institut de Recherches Internationales Servier
|chimeric antigen receptor and suicide-ligand (RQR8)
|Only notified under the "contained use" procedure. Dossier submitted on 23/04/2012.
|Randomized Phase III of haploidentical HCT with or without an add back strategy of HSV-Tk donor lymphocytes in patients with high risk acute leukemia
|-Thymidine Kinase (HSV-Tk) - selection marker